Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients

Status Recruiting

Clinical Trial Summary

Patients with histological proven advanced gastric cancer (including cancer of the esophagogastric junction (AEG) without evidence of distant metastases, who fulfill the inclusion and exclusion criteria, can be recruited in this study. There are two treatment groups (A and B). The D2 radical gastrectomy will be applied in both groups. Patients randomized into group B will be treated with an intraperitoneal (in the abdominal cavity) chemoperfusion with cisplatin(75mg/m2 max 150mg/m2 max 5L ). Patients randomized into group A will not accept intraperitoneal chemoperfusion. Patients in both groups receive 6 cycles of postoperative chemotherapy (SOX or XELOX) within 4-12 weeks after the surgical procedure and are followed up for 24 months.

Clinical Trial Description

The objective of the trial is to compare the treatment of patients with advanced gastric cancer without evidence of distant metastases treated with D2 radical gastrectomy and intraperitoneal chemoperfusion (HIPEC) and postoperative chemotherapy (Group B) and patients treated with D2 radical gastrectomy alone and postoperative chemotherapy (Group A).

The hypothesis of the trial is that D2 radical gastrectomy with intraperitoneal chemoperfusion (Group B) is superior to D2 radical gastrectomy (Group A) in terms of overall survival.

The trial is designed as a prospective, randomized, open, multicenter and parallel group study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02381847
Study type	Interventional
Source	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact	Meng Wang
Phone	86-13815890469
Email	wangmeng001@263.net
Status	Recruiting
Phase	Phase 3
Start date	January 2015
Completion date	March 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01727908` - Screening for Familial Gastric Cancer in First Degree Relatives	N/A
Completed	`NCT02337673` - Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography
Completed	`NCT02158988` - Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis	Phase 3
Recruiting	`NCT01642953` - Early Recovery After Gastric Cancer Surgery	Phase 2
Active, not recruiting	`NCT02205047` - Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Completed	`NCT01443065` - MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma	Phase 2
Completed	`NCT01758965` - Surgicel® Fibrillar for Delayed Bleeding After ESD	N/A
Completed	`NCT02528110` - Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer	Phase 2
Completed	`NCT01187212` - Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE	Phase 2
Recruiting	`NCT05880667` - Adaptive Radiation for Abdominopelvic Metastases	Phase 1
Recruiting	`NCT04345770` - Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer	Phase 2